Participant flow

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) · Source last updated 2026-03-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received an intravenous (IV) infusion of Dato DXd administered at a dose of 6.0 mg/kg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

   id

   FG000

   title

   Dato DXd 6.0 mg/kg Q3W

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         13

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         87

      type

      Progressive Disease

   3. reasons

      1. group Id

         FG000

         num Subjects

         10

      type

      Clinical Progression

   4. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Withdrawal by Subject

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         137

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         20

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         117

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

A total of 137 participants who met all inclusion criteria and no exclusion criteria were enrolled to receive Dato-DXd treatment in 50 clinical sites, North America= 15, Europe= 14, Asia Pacific= 21.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice